Schizoaffective Disorder

Introduction

Schizoaffective disorder is an episodic psychiatric illness in which symptoms meeting the criteria for schizophrenia and symptoms of a mood episode - mania, depression, or a mixed episode - occur together, with both sets of symptoms prominent for a substantial portion of the episode.¹

It sits, conceptually and diagnostically, between schizophrenia and the mood disorders with psychotic features, and is one of the trickier diagnoses to pin down in practice - not because the individual symptoms are unusual, but because getting the diagnosis right depends on the relative timing and prominence of the psychotic and mood components, which is often only clear after observing the illness over more than one episode.

It is less common than schizophrenia, with a lifetime prevalence of well under 1%, and onset is typically in early adulthood, similar to schizophrenia.

Aetiology

Schizoaffective disorder shares much of its neurobiological and genetic architecture with both schizophrenia and bipolar disorder, and is best understood as sitting on a spectrum between them rather than as an entirely separate disease process.

• Genetics: family studies show increased rates of both schizophrenia and mood disorders in relatives of people with schizoaffective disorder, supporting genetic overlap across the psychosis-mood spectrum
• Dopaminergic dysfunction: as in schizophrenia, thought to underlie the psychotic component
• Monoaminergic dysfunction: as in mood disorders, thought to underlie the depressive or manic component
• Neurodevelopmental factors: similar, though generally less pronounced, developmental risk factors to schizophrenia have been described
• Precipitants: substance misuse, major life stress and sleep disruption can precipitate episodes, as in both schizophrenia and bipolar disorder

Risk factors

• Family history of schizophrenia, schizoaffective disorder, or a mood disorder
• Substance misuse, particularly cannabis and stimulants
• Significant life stress or sleep disruption preceding an episode
• Previous psychiatric illness, particularly a prior mood or psychotic episode

Clinical features

During an episode, the person shows both features of schizophrenia (delusions, hallucinations, thought disorder, or negative symptoms) and features of a full mood episode, with both sets of symptoms co-occurring and both clearly prominent, rather than one being a minor or incidental feature of the other.¹

Psychotic features

• Delusions - persecutory, grandiose, or of reference
• Hallucinations - typically auditory
• Disorganised speech or behaviour
• First-rank symptoms (thought alienation, passivity phenomena) as seen in schizophrenia

Mood features

• Manic type: elevated or irritable mood, increased energy, grandiosity, pressured speech, reduced need for sleep - occurring together with the psychotic features described above
• Depressive type: low mood, anhedonia, reduced energy, guilt, hopelessness, biological symptoms of depression
• Mixed type: features of both mania and depression within the same episode

Between full episodes, some patients return close to their baseline, while others - more often those with a schizophrenia-predominant pattern over time - are left with residual negative or cognitive symptoms.

Mental state examination

Differential diagnosis

• Schizophrenia: psychotic symptoms persist for a substantial period without accompanying mood symptoms, or mood symptoms are brief and incidental relative to a much longer psychotic course
• Bipolar disorder or depression with psychotic features: psychotic symptoms occur exclusively during, and resolve fully with, the mood episode, and the person is free of psychosis when euthymic
• Substance-induced psychotic or mood disorder: stimulant or steroid use can produce a combined picture - always take a thorough substance history
• Delusional disorder: a single, encapsulated, well-systematised delusion without prominent mood symptoms or the broader psychotic picture of hallucinations and thought disorder
• Personality disorder: mood and perceptual disturbance are usually reactive, briefer, and lack the sustained, syndromal quality of a schizoaffective episode
• Organic causes: as for any new psychosis - encephalitis, temporal lobe epilepsy, endocrine disturbance, and substance intoxication or withdrawal

Working through the distinction in practice

Because the diagnosis turns on the relationship between two symptom clusters over time rather than on any individual symptom, the most useful clinical tool is a mood and psychosis timeline - mapping, across the whole illness, when mood symptoms were present and when psychotic symptoms were present. Three patterns emerge, and they map directly onto the three diagnoses.

Investigations

As with any new presentation of psychosis, organic and substance causes must be excluded before the diagnosis is accepted, and the same work-up applies as for a first episode of schizophrenia.

• Physical and neurological examination
• FBC, U&Es, LFTs, TFTs, calcium, glucose, B12/folate
• Urine drug screen
• ECG - baseline before antipsychotics
• Neuroimaging where the presentation is atypical or focal neurological signs are present
• Longitudinal observation - because the diagnosis depends on the relationship between mood and psychotic symptoms over time, an initial diagnosis is often provisional and is refined as the pattern of illness becomes clearer across further episodes

Two further points are specific to this diagnosis. First, a collateral history is disproportionately valuable, because the patient's own recollection of whether psychosis persisted between mood episodes is unreliable - relatives frequently give a much clearer account of the sequence. Second, reviewing old records matters more here than almost anywhere else in psychiatry: previous discharge summaries documenting mental state during euthymic periods often settle the diagnosis definitively.

Management

Treatment addresses both the psychotic and the mood component, and is broadly modelled on the combination of schizophrenia and mood disorder management. There is no separate NICE guideline for schizoaffective disorder; in practice clinicians draw on CG178 for the psychotic component and CG185 for the mood component, which is why the evidence base here is weaker and treatment more individualised than for either condition alone.

Acute episode

Management in the acute phase is driven by the mood polarity of the episode, since that determines what is added to the antipsychotic:

Maintenance

• Antipsychotic for the psychotic component - a second-generation agent is typically used first-line, as in schizophrenia²
• For manic-type episodes: add a mood stabiliser or use an antipsychotic with mood-stabilising properties; avoid antidepressants unless clearly needed and always alongside an antimanic agent
• For depressive-type episodes: an antidepressant may be added to the antipsychotic once psychotic symptoms are controlled, with the same caution about triggering mood destabilisation as in bipolar disorder
• Lithium or valproate are used as adjuncts for mood stabilisation in recurrent illness, following the same monitoring and contraindication principles as in bipolar disorder³
• Psychosocial interventions - CBT for psychosis, family intervention, and support with functioning and relapse prevention, as for schizophrenia
• Physical health monitoring - the same cardiometabolic monitoring obligations apply as for schizophrenia and bipolar disorder, given antipsychotic and mood-stabiliser use

Complications

Schizoaffective disorder carries risks from both its psychotic and mood components, and in some respects the combination is worse than either alone. Suicide risk is high - comparable to or exceeding that in schizophrenia - and is greatest during depressive and mixed episodes, particularly where insight is partially retained and the person recognises the impact the illness has had on their life. Risk-taking, disinhibition, financial harm and legal consequences occur during manic-type episodes.

Cardiometabolic disease is the leading cause of premature death, driven by the combination of antipsychotic and mood-stabiliser treatment, high smoking rates, and reduced access to routine physical healthcare. The polypharmacy typical of this diagnosis compounds the risk, and specific complications follow the individual drugs - lithium-related renal and thyroid dysfunction, valproate-related weight gain and teratogenicity, and antipsychotic-related extrapyramidal effects and hyperprolactinaemia.

Functionally, employment, education and relationships are frequently disrupted by the relapsing course, though generally less severely than in schizophrenia. Comorbid substance misuse is common, worsens both symptom control and adherence, and independently raises suicide risk. Repeated hospital admission and, in some cases, detention under the Mental Health Act carry their own lasting effects on confidence and on engagement with services.

Red flags

Prognosis

The prognosis of schizoaffective disorder is generally intermediate between schizophrenia and the mood disorders - better than schizophrenia in terms of overall functioning and negative symptom burden, but with a more relapsing and disabling course than bipolar disorder or depression on their own. This intermediate position is consistent with the view that the condition sits on a spectrum between the two rather than constituting a wholly separate disease.

The manic subtype generally carries a better prognosis than the depressive subtype, mirroring the pattern seen in bipolar disorder, with better inter-episode recovery and less residual impairment. A prominent and clearly episodic mood component, good premorbid functioning, acute rather than insidious onset, an identifiable precipitant and good adherence to maintenance treatment all predict a better outcome.

Poorer outcome is associated with a schizophrenia-predominant pattern emerging over time, prominent negative symptoms, early age of onset, comorbid substance misuse - particularly cannabis - poor insight and repeated disengagement from services. Because the diagnosis is provisional in a way that few others are, long-term follow-up with periodic reassessment of the diagnosis is standard practice, and a change of label after several years reflects the illness declaring itself rather than an earlier mistake.